Tweet
Yahoo!7 News
<img alt="" height="1" width="1" />
GSK cancer vaccine misses target in melanoma trial
Reuters
LONDON | Thu Sep 5, 2013 2:16am EDT. LONDON (Reuters) - An experimental cancer vaccine from GlaxoSmithKline failed to meet its first co-primary endpoint in a late-stage clinical trial, dealing a blow to the high-risk, high-reward project. Britain's biggest ...
GlaxoSmithKline: Mage-A3 Doesn't Meet First Co-Primary EndpointWall Street Journal
Glaxo MAGE-A3 Cancer Drug Fails to Help Patients in TrialBloomberg
GSK:MAGE-A3 Fails To Meet First Co-primary Endpoint In Late-stage Melanoma ...NASDAQ
4-traders (press release) -MarketWatch (press release)
all 7 news articles »
More...